Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients

AETHLON MEDICAL INC

Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.
First three patients treated in Hemopurifier cancer trial in Australia; DSMB safety review triggered.
Received Indian regulatory approval (CDSCO) to initiate similar oncology trial at Medanta Medicity Hospital.
Preclinical study showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier treatment.
Non-cash warrant inducement charge of $4.6M; ERTC other income $324,450.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.